Treatment of neoplasms with CCI-779/EKB-569 combination

Abstract

This invention provides the use of a combination of CCI-779 and EKB-569 in the treatment of neoplasms.

1. A method of treating a neoplasm in which uncontrolled cell proliferation results from deregulation of epidermal growth factor receptor ( EGFR )  kinase  in a mammal in need thereof, which comprises providing to said mammal  a  synergistically effective amount of a combination comprising rapamycin  42 - ester with  3   - hydroxy -   2   -( hydroxymethyl )-   2   - methylpropionic acid  (CCI-779) and  4 - dimethylamino - but -   2   - enoic acid [ 4   -(   3   - chloro -   4   - fluoro - phenylamino )-   3   - cyano -   7   - ethoxy - quinolin -   6   - yl] - amide  (EKB-569). 
     
     
       2. The method according to  claim 1 , wherein the neoplasm is renal cancer. 
     
     
       3. The method according to  claim 1 , wherein the neoplasm is soft tissue sarcoma. 
     
     
       4. The method according to  claim 1 , wherein the neoplasm is breast cancer. 
     
     
       5. The method according to  claim 1 , wherein the neoplasm is a neuroendocrine tumor of the lung. 
     
     
       6. The method according to  claim 1 , wherein the neoplasm is cervical cancer. 
     
     
       7. The method according to  claim 1 , wherein the neoplasm is uterine cancer. 
     
     
       8. The method according to  claim 1 , wherein the neoplasm is a head and neck cancer. 
     
     
       9. The method according to  claim 1 , wherein the neoplasm is glioma. 
     
     
       10. The method according to  claim 1 , wherein the neoplasm is non-small cell lung cancer. 
     
     
       11. The method according to  claim 1 , wherein the neoplasm is prostate cancer. 
     
     
       12. The method according to  claim 1 , wherein the neoplasm is pancreatic cancer. 
     
     
       13. The method according to  claim 1 , wherein the neoplasm is lymphoma. 
     
     
       14. The method according to  claim 1 , wherein the neoplasm is melanoma. 
     
     
       15. The method according to  claim 1 , wherein the neoplasm is small cell lung cancer. 
     
     
       16. The method according to  claim 1 , wherein the neoplasm is ovarian cancer. 
     
     
       17. The  A method according to  claim 1 , wherein the neoplasm is  of treating colon cancer in a mammal in need thereof, which comprises providing to said mammal a synergistically effective amount of a combination comprising rapamycin  42 - ester with  3   - hydroxy -   2   ( hydroxymethyl )-   2   - methylpropionic acid  ( CCI -   779   )  and  4   - dimethylamino - but -   2   - enoic acid [ 4   -(   3   - chloro -   4   - fluoro - phenylamino )-   3   - cyano -   7   - ethoxy - quinolin -   6   - yl] - amide  ( EKB -   569   ). 
     
     
       18. The method according to  claim 1 , wherein the neoplasm is esophageal cancer. 
     
     
       19. The method according to  claim 1 , wherein the neoplasm is gastric cancer. 
     
     
       20. The method according to  claim 1 , wherein the neoplasm is leukemia. 
     
     
       21. The  A method according to  claim 1 , wherein the neoplasm is  of treating colorectal cancer in a mammal in need thereof, which comprises providing to said mammal a synergistically effective amount of a combination comprising rapamycin  42 - ester with  3   - hydroxy -   2   ( hydroxymethyl )-   2   - methylpropionic acid  ( CCI -   779   )  and  4   - dimethylamino - but -   2   - enoic acid [ 4   -(   3   - chloro -   4   - fluoro - phenylamino )-   3   - cyano -   7   - ethoxy - quinolin -   6   - yl] - amide  ( EKB -   569   ). 
     
     
       22. The method according to  claim 1 , wherein the neoplasm is unknown primary cancer. 
     
     
       23. A method of treating a neoplasm in which uncontrolled cell proliferation results from deregulation of epidermal growth factor receptor ( EGFR )  kinase  in a mammal in need thereof, which comprises providing to said mammal an effective amount of a synergistic combination comprising rapamycin  42 - ester with  3   - hydroxy -   2   -( hydroxymethyl )-   2   - methylpropionic acid  (CCI-779) and  4 - dimethylamino - but -   2   - enoic acid [ 4   -(   3   - chloro -   4   - fluoro - phenylamino )-   3   - cyano -   7   - ethoxy - quinolin -   6   - yl] - amide  (EKB-569), wherein either CCI-779, EKB-569, or both are provided in subtherapeutically effective amounts. 
     
     
       24. The method according to  claim 23  in which CCI-779 is provided in a subtherapeutically effective amount. 
     
     
       25. The method according to  claim 23  in which EKB-569 is provided in a subtherapeutically effective amount. 
     
     
       26. The method according to  claim 23  in which both CCI-779 and EKB-569 are provided in subtherapeutically effective amounts. 
     
     
       27. An antineoplastic combination useful in treatment of neoplasms in which uncontrolled cell proliferation results from by deregulation of epidermal growth factor receptor kinase which comprises an antineoplastic effective amount of a synergistic combination of rapamycin  42 - ester with  3   - hydroxy -   2   -( hydroxymethyl )-   2   - methylpropionic acid  (CCI-779) and  4 - dimethylamino - but -   2   - enoic acid [ 4   -(   3   - chloro -   4   - fluoro - phenylamino )-   3   - cyano -   7   - ethoxy - quinolin -   6   - yl] - amide  (EKB-569).